Combination Vaccine and Multivalent Vaccine Industry Research Report 2025

Summary

According to APO Research, The global Combination Vaccine and Multivalent Vaccine market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Combination Vaccine and Multivalent Vaccine include BioNTech, Dynavax, Moderna, Novavax, Pfizer, Sanofi Pasteur, AIM Bio, Beijing Institute of Biological Products and Chengdu Institute of Biological Products, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Combination Vaccine and Multivalent Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Combination Vaccine and Multivalent Vaccine.
The Combination Vaccine and Multivalent Vaccine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Combination Vaccine and Multivalent Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Combination Vaccine and Multivalent Vaccine Segment by Company

BioNTech
Dynavax
Moderna
Novavax
Pfizer
Sanofi Pasteur
AIM Bio
Beijing Institute of Biological Products
Chengdu Institute of Biological Products
Antejin Biotechnology
GlaxoSmithKline
Kangtai Bio
Sinovac
Lanzhou Institute of Biological Products
Minhai Biological
Merck & Co.
Wanbangde Pharmaceutical
Wantai Biological
Walvax
Wuhan Institute of Biological Products
Zhifei Biological
Sino Biopharm
Combination Vaccine and Multivalent Vaccine Segment by Type

Combination Vaccine
Multivalent Vaccine
Combination Vaccine and Multivalent Vaccine Segment by Application

Hospital
Centers for Disease Control and Prevention
Others
Combination Vaccine and Multivalent Vaccine Segment by Application

Hospital
Centers for Disease Control and Prevention
Others
Combination Vaccine and Multivalent Vaccine Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Combination Vaccine and Multivalent Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Combination Vaccine and Multivalent Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Combination Vaccine and Multivalent Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Combination Vaccine and Multivalent Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Combination Vaccine and Multivalent Vaccine by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Combination Vaccine
2.2.3 Multivalent Vaccine
2.3 Combination Vaccine and Multivalent Vaccine by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospital
2.3.3 Centers for Disease Control and Prevention
2.3.4 Others
2.4 Assumptions and Limitations
3 Combination Vaccine and Multivalent Vaccine Breakdown Data by Type
3.1 Global Combination Vaccine and Multivalent Vaccine Historic Market Size by Type (2020-2025)
3.2 Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Type (2026-2031)
4 Combination Vaccine and Multivalent Vaccine Breakdown Data by Application
4.1 Global Combination Vaccine and Multivalent Vaccine Historic Market Size by Application (2020-2025)
4.2 Global Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Combination Vaccine and Multivalent Vaccine Market Perspective (2020-2031)
5.2 Global Combination Vaccine and Multivalent Vaccine Growth Trends by Region
5.2.1 Global Combination Vaccine and Multivalent Vaccine Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Combination Vaccine and Multivalent Vaccine Historic Market Size by Region (2020-2025)
5.2.3 Combination Vaccine and Multivalent Vaccine Forecasted Market Size by Region (2026-2031)
5.3 Combination Vaccine and Multivalent Vaccine Market Dynamics
5.3.1 Combination Vaccine and Multivalent Vaccine Industry Trends
5.3.2 Combination Vaccine and Multivalent Vaccine Market Drivers
5.3.3 Combination Vaccine and Multivalent Vaccine Market Challenges
5.3.4 Combination Vaccine and Multivalent Vaccine Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Combination Vaccine and Multivalent Vaccine Players by Revenue
6.1.1 Global Top Combination Vaccine and Multivalent Vaccine Players by Revenue (2020-2025)
6.1.2 Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Players (2020-2025)
6.2 Global Combination Vaccine and Multivalent Vaccine Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Combination Vaccine and Multivalent Vaccine Head Office and Area Served
6.4 Global Combination Vaccine and Multivalent Vaccine Players, Product Type & Application
6.5 Global Combination Vaccine and Multivalent Vaccine Manufacturers Established Date
6.6 Global Combination Vaccine and Multivalent Vaccine Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Combination Vaccine and Multivalent Vaccine Market Size (2020-2031)
7.2 North America Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2020-2025)
7.4 North America Combination Vaccine and Multivalent Vaccine Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Combination Vaccine and Multivalent Vaccine Market Size (2020-2031)
8.2 Europe Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2020-2025)
8.4 Europe Combination Vaccine and Multivalent Vaccine Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size (2020-2031)
9.2 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Country (2020-2025)
9.4 Asia-Pacific Combination Vaccine and Multivalent Vaccine Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Combination Vaccine and Multivalent Vaccine Market Size (2020-2031)
10.2 South America Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Combination Vaccine and Multivalent Vaccine Market Size by Country (2020-2025)
10.4 South America Combination Vaccine and Multivalent Vaccine Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size (2020-2031)
11.2 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2020-2025)
11.4 Middle East & Africa Combination Vaccine and Multivalent Vaccine Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 BioNTech
12.1.1 BioNTech Company Information
12.1.2 BioNTech Business Overview
12.1.3 BioNTech Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.1.4 BioNTech Combination Vaccine and Multivalent Vaccine Product Portfolio
12.1.5 BioNTech Recent Developments
12.2 Dynavax
12.2.1 Dynavax Company Information
12.2.2 Dynavax Business Overview
12.2.3 Dynavax Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.2.4 Dynavax Combination Vaccine and Multivalent Vaccine Product Portfolio
12.2.5 Dynavax Recent Developments
12.3 Moderna
12.3.1 Moderna Company Information
12.3.2 Moderna Business Overview
12.3.3 Moderna Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.3.4 Moderna Combination Vaccine and Multivalent Vaccine Product Portfolio
12.3.5 Moderna Recent Developments
12.4 Novavax
12.4.1 Novavax Company Information
12.4.2 Novavax Business Overview
12.4.3 Novavax Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.4.4 Novavax Combination Vaccine and Multivalent Vaccine Product Portfolio
12.4.5 Novavax Recent Developments
12.5 Pfizer
12.5.1 Pfizer Company Information
12.5.2 Pfizer Business Overview
12.5.3 Pfizer Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.5.4 Pfizer Combination Vaccine and Multivalent Vaccine Product Portfolio
12.5.5 Pfizer Recent Developments
12.6 Sanofi Pasteur
12.6.1 Sanofi Pasteur Company Information
12.6.2 Sanofi Pasteur Business Overview
12.6.3 Sanofi Pasteur Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.6.4 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Portfolio
12.6.5 Sanofi Pasteur Recent Developments
12.7 AIM Bio
12.7.1 AIM Bio Company Information
12.7.2 AIM Bio Business Overview
12.7.3 AIM Bio Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.7.4 AIM Bio Combination Vaccine and Multivalent Vaccine Product Portfolio
12.7.5 AIM Bio Recent Developments
12.8 Beijing Institute of Biological Products
12.8.1 Beijing Institute of Biological Products Company Information
12.8.2 Beijing Institute of Biological Products Business Overview
12.8.3 Beijing Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.8.4 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
12.8.5 Beijing Institute of Biological Products Recent Developments
12.9 Chengdu Institute of Biological Products
12.9.1 Chengdu Institute of Biological Products Company Information
12.9.2 Chengdu Institute of Biological Products Business Overview
12.9.3 Chengdu Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.9.4 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
12.9.5 Chengdu Institute of Biological Products Recent Developments
12.10 Antejin Biotechnology
12.10.1 Antejin Biotechnology Company Information
12.10.2 Antejin Biotechnology Business Overview
12.10.3 Antejin Biotechnology Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.10.4 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Portfolio
12.10.5 Antejin Biotechnology Recent Developments
12.11 GlaxoSmithKline
12.11.1 GlaxoSmithKline Company Information
12.11.2 GlaxoSmithKline Business Overview
12.11.3 GlaxoSmithKline Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.11.4 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Portfolio
12.11.5 GlaxoSmithKline Recent Developments
12.12 Kangtai Bio
12.12.1 Kangtai Bio Company Information
12.12.2 Kangtai Bio Business Overview
12.12.3 Kangtai Bio Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.12.4 Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Portfolio
12.12.5 Kangtai Bio Recent Developments
12.13 Sinovac
12.13.1 Sinovac Company Information
12.13.2 Sinovac Business Overview
12.13.3 Sinovac Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.13.4 Sinovac Combination Vaccine and Multivalent Vaccine Product Portfolio
12.13.5 Sinovac Recent Developments
12.14 Lanzhou Institute of Biological Products
12.14.1 Lanzhou Institute of Biological Products Company Information
12.14.2 Lanzhou Institute of Biological Products Business Overview
12.14.3 Lanzhou Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.14.4 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
12.14.5 Lanzhou Institute of Biological Products Recent Developments
12.15 Minhai Biological
12.15.1 Minhai Biological Company Information
12.15.2 Minhai Biological Business Overview
12.15.3 Minhai Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.15.4 Minhai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
12.15.5 Minhai Biological Recent Developments
12.16 Merck & Co.
12.16.1 Merck & Co. Company Information
12.16.2 Merck & Co. Business Overview
12.16.3 Merck & Co. Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.16.4 Merck & Co. Combination Vaccine and Multivalent Vaccine Product Portfolio
12.16.5 Merck & Co. Recent Developments
12.17 Wanbangde Pharmaceutical
12.17.1 Wanbangde Pharmaceutical Company Information
12.17.2 Wanbangde Pharmaceutical Business Overview
12.17.3 Wanbangde Pharmaceutical Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.17.4 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Portfolio
12.17.5 Wanbangde Pharmaceutical Recent Developments
12.18 Wantai Biological
12.18.1 Wantai Biological Company Information
12.18.2 Wantai Biological Business Overview
12.18.3 Wantai Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.18.4 Wantai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
12.18.5 Wantai Biological Recent Developments
12.19 Walvax
12.19.1 Walvax Company Information
12.19.2 Walvax Business Overview
12.19.3 Walvax Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.19.4 Walvax Combination Vaccine and Multivalent Vaccine Product Portfolio
12.19.5 Walvax Recent Developments
12.20 Wuhan Institute of Biological Products
12.20.1 Wuhan Institute of Biological Products Company Information
12.20.2 Wuhan Institute of Biological Products Business Overview
12.20.3 Wuhan Institute of Biological Products Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.20.4 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
12.20.5 Wuhan Institute of Biological Products Recent Developments
12.21 Zhifei Biological
12.21.1 Zhifei Biological Company Information
12.21.2 Zhifei Biological Business Overview
12.21.3 Zhifei Biological Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.21.4 Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
12.21.5 Zhifei Biological Recent Developments
12.22 Sino Biopharm
12.22.1 Sino Biopharm Company Information
12.22.2 Sino Biopharm Business Overview
12.22.3 Sino Biopharm Revenue in Combination Vaccine and Multivalent Vaccine Business (2020-2025)
12.22.4 Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Portfolio
12.22.5 Sino Biopharm Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings